McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill

Core Viewpoint - McKesson Corporation has agreed to sell its Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to focus on oncology and biopharma services while continuing to support the Canadian healthcare market through distribution [1][2]. Group 1: Sale Details - The sale of Rexall and Well.ca will allow McKesson to streamline operations and prioritize investments in high-growth areas [2]. - Birch Hill Equity Partners will invest in expanding Rexall and Well.ca, enhancing their services across more locations in Canada, while McKesson Canada will remain their wholesale distribution supplier until the transaction is finalized [3]. Group 2: Market Prospects - The healthcare services market is projected to grow from $8.96 trillion in 2024 to $10.91 trillion by 2028, at a CAGR of 5% [4]. - Key growth drivers include the expansion of telehealth, addressing workforce shortages, health equity initiatives, and the adoption of value-based care models [4]. Group 3: Stock Performance - McKesson's shares have increased by 11.2% year to date, outperforming the industry growth of 2.5% and the S&P 500's rise of 15.7% [5].